Furthermore, the study of tumour-infiltrating lymphocytes has become a hotspot, and tumour-associated macrophages (TAMs), CD8 + T cells and CD4 + T cells have effects on patient prognosis and are correlated with the efficacy of immunotherapy and chemotherapy in the clinic [7–9]. This evidence concerns the gene CD8A and neoplasm.